AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: http://www.ajptr.com/

The Role of Pharmacogenomics in Personalized Therapeutics: A Crossroad Between Pharmaceutical and Biomedical Sciences

Bishal Sarkar[1*], Shiva Das[2]

1.Mata Gujri College of Pharmacy, Kishanganj, Bihar, 855107, India

2.Mata Gujri College of Allied Health and Paramedical Sciences, Kishanganj, Bihar, 855107, India

ABSTRACT

Pharmacogenomics, an interdisciplinary basis of personalized medicine, explains the influence of genomic variation on drug disposition, response, and toxicity. Pharmacogenomics is exemplified in both mechanistic and clinical concepts, demarcating its crossing point between pharmaceutical and biomedical sciences. Polymorphisms in drug-metabolizing enzymes (e.g., CYP2D6, CYP2C9, CYP2C19), transporters (e.g., ABCB1, SLCO1B1), and pharmacologic targets (e.g., VKORC1, EGFR) alter pharmacokinetic and pharmacodynamic profiles, making justifications for individualized therapeutic strategies. The paper defines the pharmacogenomic uses in oncology, cardiology, and psychiatry fields for which pharmacogenomic markers (e.g., HER2, KRAS, CYP2C19) are now a requirement to maximize the effect of treatment and minimize drug reactions. The review also points towards the pivotal role of allied biomedical sciences—i.e., human physiology, clinical biochemistry, and molecular diagnostics to locating gene–drug interactions within the frame of everyday clinical phenotypes. Despite the great leaps, clinical translation remains beset by issues such as fragmentation of regulation, bioethics, population-specific gaps in data, and a lack of clinical genomic literacy. Technologies in the form of next-generation sequencing, multi-omics fusion, and artificial intelligence-based decision support systems, however, offer the potential for scalable and equitable deployment. In summary, pharmacogenomics is a paradigm shift towards genotype-directed pharmacotherapy. For its successful incorporation in clinical medicine, interdisciplinary collaboration, strong informatics support, and harmonized regulatory policies need to supply rational, safe, and personalized drug therapy.

Keywords: Pharmacogenomics, Personalized Medicine, Drug Metabolism, Genetic Polymorphism, Interdisciplinary Medicine

*Corresponding Author Email: grpbishal@gmail.com

Received 20 May 2025, Accepted 17 June 2025

Please cite this article as: Sarkar B *et al.*, The Role of Pharmacogenomics in Personalized Therapeutics: A Crossroad Between Pharmaceutical and Biomedical Sciences. American Journal of PharmTech Research 2025.

INTRODUCTION

Personalized medicine is a new paradigm in contemporary healthcare that seeks to maximize therapy based on an individual's genetic, physiologic, and environmental characteristics. Pharmacogenomics, one of the pillars behind this paradigm, is the science that explores the impact of genetic differences on the response of an individual to drugs and thus how drugs can be rendered more specific, safe, and effective [1,2]. Pharmacotherapy has in the past depended on fixed dosing regimens with the expectation of uniformity in drug response, distribution, and metabolism among populations. Drug response intersubject variability is, however, well documented with others showing sub-therapeutic effects or ADRs on dosages that are advised [3]. All these differences can most frequently be explained by drug-metabolizing enzyme gene polymorphisms (e.g., CYP2D6, CYP2C9), transporters (e.g., ABCB1), and drug targets (e.g., VKORC1) and influence the pharmacokinetics and pharmacodynamics of drugs [4–6]. Pharmacogenomics not only helps to identify such genetic determinants but also helps patient stratification into responders and non-responders or those at greater risk for ADRs [7]. Such data are useful in individualizing drug selection and dosing regimens, particularly in therapeutic modalities like oncology, cardiology, psychiatry, and infectious disease[8–10]. Though based in pharmaceutical sciences i.e., pharmacology and pharmacokinetics pharmacogenomics must interfacing exhaustively with biomedical sciences like human physiology, biochemistry, molecular biology, and pathology in order to understand gene–drug interactions and systemic responses in depth [11].



Figure 1: Implementing pharmacogenomics

For example, the pharmacogenomic profile of a drug should be understood together with physiological factors like hepatic or renal impairment, comorbidities, age, and sex, all of which are capable of affecting therapeutic effects [12, 13]. In addition, as high-throughput genomic technologies and bioinformatics tools have come into existence, pharmacogenomic studies have been able to

screen entire genomes for drug-related genetic variation. This has driven the creation of clinical decision support systems (CDSS) and pharmacogenomic biomarkers, which are increasingly being integrated into electronic health records and clinical workflow [14,15, 16]. In spite of all of these advances, several barriers to the application of pharmacogenomics in the routine clinical practice still exist. These include low clinician awareness, no concurred guidelines, ethical issues surrounding genetic testing, and variability in access to genomic resources between healthcare systems [177, 18]. All of these can be overcome by an interdisciplinary, multidisciplinary approach by pharmacists, clinicians, geneticists, bioinformaticians, and regulatory bodies. This review strives to present a comprehensive tour of pharmacogenomics as the basis of personalized therapeutics with an emphasis on the interdisciplinary nexus of pharmaceutical and biomedical sciences. The review briefly mentions the molecular underpinnings of drug–gene interactions, clinical utility in prioritized diseases, and the way forward with artificial intelligence and pharmacoinformatics for guiding personalized healthcare.

Pharmacogenomic Background of Personalized Therapy

Variation of Drug-Metabolizing Enzymes

Variation in drug-metabolizing enzymes is the foundation of inter individual differences in drug metabolism, action, and toxicity. Such variations, frequently due to single nucleotide polymorphisms (SNPs), have the potential to impact enzyme function significantly complete loss to ultra-rapid metabolism—thus influencing plasma drug levels and clinical responses [19,20]. The most widely studied families of drug-metabolizing enzymes are the cytochrome P450 (CYP450) superfamily. Of these, CYP2D6, CYP2C9, CYP2C19, and CYP3A4/5 are important in metabolizing more than 80% of the drugs currently in use [21]. CYP2D6, for instance, metabolizes many antidepressants, beta-blockers, and opioids. Genetic polymorphism in CYP2D6 can result in phenotypes that can be categorized as poor, intermediate, extensive, or ultra-rapid metabolizers, each of which responds with significantly different effects to normal dosing [22]. Warfarin metabolism, too, is regulated by CYP2C9 polymorphisms. CYP2C9 *2 or *3 allele carriers have decreased enzyme activity and a higher risk of bleeding as a result of drug accumulation [23]. In contrast, CYP2C19 polymorphisms affect the bioactivation of the widely used antiplatelet drug clopidogrel. Subjects carrying CYP2C19 loss-of-function alleles (i.e., *2, *3) have diminished antiplatelet effects, with an elevated risk of cardiovascular events [24]. Besides CYP enzymes, phase II enzymes, such as UDP-glucuronosyl transferases (UGTs) and glutathione S-transferases (GSTs), are also subject to genetic polymorphism that influences conjugation and drug detoxification [25]. UGT1A1 polymorphism (UGT1A1 28 allele), for instance, influences metabolism of irinotecan,

which makes patients prone to severe neutropenia [26]. Such genetic variations require genotype-directed dosing recommendations that have been included in clinical practice guidelines by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and FDA pharmacogenomic labeling [27].



Figure 2: Impact of Genetic Variations on Drug Metabolism

Effect on Pharmacokinetics and Pharmacodynamics

Pharmacogenomic heterogeneity impacts both pharmacokinetics (PK)–the way the body metabolizes, distributes, excretes, and absorbs a drug–and pharmacodynamics (PD)–the way the drug acts on biological targets to produce effects [28]. At the pharmacokinetic level, polymorphisms of drug transporters like ABCB1 (P-glycoprotein) affect drug bioavailability and tissue distribution. For instance, ABCB1 polymorphisms may affect digoxin absorption or prevent penetration of chemotherapeutic agents and antiepileptic drugs into the brain [29]. Polymorphisms in SLCO1B1, a gene coding for hepatic uptake transporter OATP1B1, have considerable effects on the clearance of statins. Carriers of the SLCO1B1 5 allele are at risk for statin-induced myopathy by decreased hepatic uptake and increased plasma concentrations [30]. Pharmacodynamically, drug target or receptor polymorphisms could affect drug response and toxicity. To illustrate, VKORC1 gene polymorphisms determine warfarin sensitivity by altering the expression of the target enzyme, necessitating individualized dosing to avoid over-anticoagulation [31]. Similarly, ADRB1

and ADRB2 beta-adrenergic receptor polymorphisms have been associated with altered response to beta-blockers and bronchodilators in cardiovascular and respiratory diseases [32]. Understandings of both PK and PD variation allow for whole pharmacogenomic evaluation, with improved forecast of therapeutic action, avoidance of side effects, and maximization of treatment effect [33]. This understanding is essential in high-risk therapy (e.g., oncology, anticoagulation, and immunosuppression), where therapeutic windows are narrow and inter patient variation is fatal. Thus, pharamcogenomic testing adopted in practice not only increases therapeutic accuracy but also closes the gap between genotype and drug phenotypic response, particularly when combined with allied biomedical factors like renal/hepatic function, inflammatory markers, and biomarker levels [34].

Interdisciplinary Integration

Physiology and Biochemistry Contribution to Drug Action

Pharmacogenomics cannot be read and used in its entirety without considering the physiological and biochemical environment wherein drug response and metabolism take place. Human physiology also plays an important role in controlling the expression, activity, and regulation of drug-metabolizing enzymes and transporters. Age, sex, organ function (liver, kidney), hormonal status, nutrition, and circadian rhythms all play a role in how one responds to pharmacotherapy, irrespective of genotype [35]. For example, hepatic blood flow, renal clearance, intestinal motility, and plasma protein binding capacity are physiologically controlled parameters and have bearing on the pharmacokinetics of drugs. In neonates and elderly subjects, decreased enzymatic activity and organ perfusion impairment are likely to result in prolonged drug half-life and increased risk of toxicity [36]. Besides, cytokine and inflammatory mediator interaction in disease conditions like infection, cancer, or autoimmune disease can down regulate the CYP enzymes, thereby altering the drug metabolism even in genetically normal metabolizers [37]. Biochemistry then goes on to explain molecular mechanisms of drug–enzyme interaction, enzyme kinetics, substrate specificity, and how post-translational modification affects enzyme function [38]. To illustrate, glucuronidation and sulfation, two principal phase II metabolic reactions, are not only affected by genetic polymorphisms but also by the intracellular levels of cofactors like UDP-glucuronic acid and PAPS (3′-phosphoadenosine-5′-phosphosulfate), whose biosynthesis depends upon the availability of nutrients and overall metabolic status [39]. Also determinative are physiological factors like body mass index (BMI), the status of hydration, and pH gradients across tissues that affect the solubility, distribution, and cellular binding of drugs. They are particularly important in the instance of lipophilic drugs or drug therapeutic windows, in which even slight variation can lead to

subtherapeutic or toxicities [40]. The integration of pharmacogenomic information with biochemical and physiological tests can thus maximize dose estimation, predict drug–drug and drug–disease interactions, and identify patients at risk for failure or toxicity of treatment. Such integrative analysis goes beyond genotype-directed personalization of therapy and paves the way to holistic pharmacological treatments.



Figure 3: Factors Influencing Drug Action and Metabolism

Pharmacogenomic Data in Clinical Diagnosis

Pharmacogenomics has revolutionized conventional diagnostics using genetic biomarkers that predict drug response, adverse drug reactions (ADRs), and disease progression. The integration of such biomarkers in clinical diagnostics enhances personalized therapeutic strategies and decision-making for refractory or high-risk conditions [41]. In cancer, companion diagnostic testing like KRAS mutation testing for cetuximab, trastuzumab HER2 testing, and EGFR mutation analysis for tyrosine kinase inhibitors is currently standard of care. Such tests inform therapy choice and the possibility of predicting response to targeted agents, enhance clinical outcomes, and reduce unnecessary exposure to ineffective therapy [42]. Outside of oncology, pharmacogenomic testing is increasing in psychiatry (e.g., CYP2D6/CYP2C19 genotyping for antidepressants), cardiology (e.g., CYP2C9/VKORC1 genotyping for warfarin), and infectious disease (e.g., HLA-B*5701 screening for hypersensitivity to abacavir). Not only does the testing improve safety and efficacy but also it saves healthcare dollars as trial-and-error prescribing is minimized [35,41]. Combining genomic analysis with clinical biochemistry and physiological testing—e.g., liver function tests, renal function tests, ECGs, and inflammatory markers—employs a multidimensional diagnostic model. The combination enables clinicians to appraise the patient's pharmacogenomic profile in real-life biological context, allowing drug selection to be tailored to the individual's genetic,

metabolic, and systemic health status. This interdisciplinarity emphasizes the need for an interprofessional response from clinicians, pharmacists, pathologists, and biomedical scientists to transform pharmacogenomic information into clinically relevant interventions.

Clinical Applications of Pharmacogenomics

Pharmacogenomics has substantially advanced clinical therapeutics, particularly where the therapeutic response is extremely variable and gene-dependent. Some of the key fields where pharmacogenomic uses are presently standard or highly promising include oncology, cardiology, and psychiatry. In all of these fields, patient-specific information on gene variants helps tailor therapy, diminishes side effects, and maximizes therapy effectiveness [43].

Oncology

Treatment for cancer has been at the forefront of personalized medicine, with drug selection, dosing, and candidacy for targeted therapies based on pharmacogenomic biomarkers. For instance, EGFR gene mutations are used to predict responsiveness to tyrosine kinase inhibitors erlotinib and gefitinib in NSCLC [44]. Similarly, HER2 overexpression, as detected by immunohistochemistry or FISH, identifies patients with breast cancer eligible to receive therapy with trastuzumab (Herceptin) [45]. Another most important biomarker is KRAS, a downstream effector of the EGFR pathway. KRAS mutations correlate with resistance to cetuximab and panitumumab in colorectal cancer, and testing is now required before initiating therapy [46]. These are a few examples of how the practice of pharmacogenomics has revolutionized cancer treatment from cytotoxic drugs to precision target therapies.

Cardiology

Pharmacogenomics is used in cardiology to prevent adverse drug reaction (ADRs) and therapeutic failure, especially with drugs having a narrow therapeutic index such as warfarin. Warfarin's anticoagulant activity is determined by polymorphism of CYP2C9 (influence on metabolism) and VKORC1 (influence on drug target sensitivity). Carriers of CYP2C9 *2/*3 or VKORC1 -1639G>A alleles need lower doses of warfarin to avoid risk of bleeding complications [47]. Yet another widely investigated case is clopidogrel, which is an active prodrug that is needed to be activated by CYP2C19. Homozygotes for the CYP2C19 *2/*3 alleles have decreased enzyme activity and dysfunctional conversion of the drug into the active metabolite with associated increased risk of subsequent cardiovascular events after stent implantation [48, 49].



Figure 4: Pharmacogenomic Applications in Clinical Fields

Psychiatry

Psychiatric pharmacogenomics is being increasingly applied for the optimization of treatment with antidepressants and antipsychotics with high within-class variation of response and side-effect profiles. The selective serotonin reuptake inhibitors (SSRIs) fluoxetine, paroxetine, and sertraline are metabolized by CYP2D6 and CYP2C19 polymorphisms [50]. Poor metabolizers may be at risk for high plasma drug levels, and ultra-rapid metabolizers are likely to fail to achieve drug levels necessary for therapeutic effect. In the same way, antipsychotic medications like aripiprazole and risperidone are metabolized by CYP2D6; genotype-directed adjustments will avoid extrapyramidal side effects or sedation [51]. In addition, pharmacogenomic information are facilitating decisions regarding polypharmacy therapy in treatment-resistant depression, bipolar disorder, and schizophrenia [52,53].

Table 1: Pharmacogenomic Biomarkers and Their Applications [43-53]

Therapeutic Area	Drug	Gene	Variant	Clinical Applications
Oncology	Erlotinib, Gefitinib	*EGFR*	L858R, Exon 19 del	Predicts response in NSCLC
	Trastuzumab	*HER2/ERBB2*	HER2 amplification	Guides therapy in HER2+ breast cancer
	Cetuximab, Panitumumab	*KRAS*	Exon 2 mutations	Resistance in colorectal cancer
Cardiology	Warfarin	*CYP2C9, VKORC1*	*2, *3 / -1639G>A	Dose adjustment to avoid bleeding
	Clopidogrel	*CYP2C19*	*2, *3	Poor metabolism leads to therapy failure
Psychiatry	SSRIs	*CYP2D6, CYP2C19*	Various PM/UM alleles	Adjust dose to prevent toxicity or inefficacy
	Risperidone, Aripiprazole	*CYP2D6*	*3, *4, *5, *6	Prevents side effects via dose personalization

Challenges and Opportunities in Pharmacogenomic Implementation

Although the increasing promise of pharmacogenomics to offer tailored drugs has great appeal, its routine clinical utilization is faced with numerous scientific, clinical, ethical, and regulatory challenges. Although some specialist disciplines and health systems have successfully taken early moves towards implementing pharmacogenomic testing, its regular application in various healthcare environments remains minimal.

Ethical and Privacy Concerns

Among the most significant threats to pharmacogenomics is controlling ethical issues regarding genetic testing. Genetic data are very personal and can disclose susceptibility to illnesses beyond drug reaction. Genetic discrimination, consent, and abuse of data are dreaded [54]. Most patients and doctors dread possession and disclosure of genetic data, particularly in the absence of strict regulatory guidelines. Additionally, ethical issues are implicated in predictive pharmacogenomic screening, especially in children and mental disorders, where genetic markers can be employed prior to the onset of symptoms. Voluntary, informed consent and right not to know certain genetic information are essential ethical considerations which should be maintained [55].

Regulatory and Standardization Barriers

Again, a significant obstacle is the absence of overarching regulation and standardization for pharmacogenomic testing. Agencies like the FDA have placed pharmacogenomic data on labels, but clinical use is not standardized and varies by institution and country in terms of interpretation and application [56]. In addition, although organizations such as Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) offer evidence-based genotype-directed drug dosing guidelines, the latter are not standardized and test quality and interpretation of laboratory results significantly vary [57]. There is a dire need for harmonization of testing protocols, genotype–phenotype correlation validation, and regulation of clinical-grade genotyping platforms.

Gaps in Healthcare Provider Education

One of the most significant implementation challenges is limited pharmacogenomics literacy among providers. Physicians and nurses have reported inadequate training in genetics, molecular pharmacology, and interpretation of pharmacogenomic results, leading to hesitation in ordering tests or implementing test results in treatment [58]. Recent polls indicate that few, if any, medical and pharmacy school curricula provide adequate coverage of pharmacogenomics, and there are limited opportunities for continued professional education [59]. In the absence of directed training and

multidisciplinary teamwork, even clinically efficacious pharmacogenomic utilities may be inadequately utilized.

Economic and Infrastructure Constraints

The price of pharmacogenomic testing, particularly in low- and middle-income countries (LMICs), is a major barrier. Although the cost of genotyping is falling, health systems might not have infrastructure, e.g., bioinformatics software, electronic health records (EHRs) linked to clinical decision support systems (CDSS), and skilled clinicians to effectively use and interpret tests [60]. Moreover, economic analyses of pharmacogenomics tend to underestimate long-term cost savings in terms of avoided adverse events, hospitalization, and treatment failure. Additional cost-effectiveness studies and payment models must be conducted to persuade payers and policymakers regarding the value proposition of pharmacogenomic-guided therapy.

Opportunity: Towards Equitable, AI-Driven Pharmacogenomics

In the midst of these difficulties, artificial intelligence (AI), machine learning, and big data analytics hold the promise to provide a solution. They can be employed to enhance the scrutiny of intricate genomic data, anticipate multi-gene interactions, and tailor drug treatment in real time. However, to avail themselves of that potential, multi stakeholder cooperation between academia, industry, clinicians, and patients is crucial. Development of inclusive genomic databases that reflect populations across the globe, especially underrepresented ethnic populations, will also be crucial in achieving equal application of pharmacogenomics.

CONCLUSION

Pharmacogenomics is a conceptual advance toward the quest for individualized or tailored medicine, which holds the promise of revolutionizing drug treatment by aligning the treatment regimen with one's genetic makeup. Pharmacogenomics allows clinicians to tailor drug choice, dose, and treatment duration to maximize therapeutic effect and avoid adverse effects of drugs—two pillars on which effective and safe pharmacotherapy rests. As has been clear through this overview, pharmacogenomics is not the territory of a single discipline but the confluence of pharmaceutical sciences and allied biomedical sciences. It must be paired with genetics, pharmacology, physiology, biochemistry, pathology, and informatics in order to attain productive clinical application, supporting the importance of an actual interdisciplinary approach. From oncology, where genomic biomarkers guide targeted therapy, to cardiology and psychiatry, where genotyping is improving dose safety and response predictability, clinical uses for pharmacogenomics are rapidly becoming a reality and redefining therapeutic strategies. But worldwide adoption is fraught with challenges. Ethical concerns regarding genetic privacy, the

requirement for uniform guidelines, the limitation of provider education, and budget issues in resource-limited settings all challenge wholesale integration of pharmacogenomic practice into daily clinical practice. In addition, health disparities and the lack of well-representation of minority populations in pharmacogenomics studies risk limiting world use and equity of genomic medicine. However, upcoming breakthroughs in artificial intelligence, pharmacoinformatics, next-generation sequencing, and multi-omics platforms are set to accelerate the application of pharmacogenomics within electronic health records and decision-support systems, facilitating real-time, evidence-driven clinical action. Inclusive, population-relevant pharmacogenomic databases will further promote precision medicine practice worldwide. In short, pharmacogenomics has already started reshaping contemporary therapeutics, and further advancement would rely on interdisciplinary collaboration, educational reform, and harmonization of regulation. By integrating pharmacy with allied biomedical sciences, pharmacogenomics is the gateway to safer, smarter, and more personal drug therapy moving toward the goal of not only controlling the disease, but controlling the patient.

REFERENCES

1. Cheng Q, Yang W, Raimondi SC, Bhatia S, Relling MV, Evans WE. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005; 37:878–82.
2. Sorich MJ, McKinnon RA. Personalized medicine: potential, barriers and contemporary issues. Curr Drug Metab 2012; 13:1000–6.
3. Brazell C, Freeman A, Mosteller M. Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance. Br J Clin Pharmacol 2002; 53:224–31.
4. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001; 14:611–50.
5. Phillips KA, Veenstra DL, Oren EEO, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286:2270–9.
6. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002; 20:1–10.
7. Akagah B, Lormier AT, Fournet A, Figadère B. Oxidation of anti-parasitic 2-substituted quinolines using metalloporphyrin catalysts: scale-up of a biomimetic reaction for metabolite production of drug candidates. Org Biomol Chem 2008; 6:4494–7.

8. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet 2003; 33:518–21.
9. Evans W, Johnson JA. Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2:9–39.
10. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ 1998; 316:1295–8.
11. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharmsci 2000; 2:E29.
12. Magic Z, Supic G, Brankovic-Magic M. Towards targeted epigenetic therapy of cancer. J BUON 2009; 14(Suppl 1):S79–88.
13. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005; 307:1072–9.
14. Schlichting I, Berendzen J, Chu K, Stock AM, Maves SA, Benson DE, et al. The catalytic pathway of cytochrome p450cam at atomic resolution. Science 2000; 287(5458):1615–22.
15. Kager L. Genomic strategies to improve outcome and individualize therapy in cancer: the paradigm of childhood acute lymphoblastic leukemia. J BUON 2009;14(Suppl 1):S181–6.
16. Hewitt P. Tufts Centre for the Study of Drug Development Pegs Cost of a New Prescription Medicine at $802 Million. Boston: Tufts Center for the Study of Drug Development; 2001.
17. Cheok MH, Pottier N, Kager L, Yanishevski Y, Pei D, Hu S, et al. Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol 2009; 46:39–51.
18. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151–85.
19. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409:928–33.
20. Andersen JB, Szumlanski C, Weinshilboum RM, Krynetski EY, Evans WE. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998; 87:108–11.

21. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyl transferase deficient heart transplant recipient. Lancet 1993; 341:1151.
22. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473–8.
23. Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyl transferase in acute lymphoblastic leukemia. Blood 2006;107:843–4.
24. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Sandlund JT, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301:393–403.
25. Drendel A. Pharmacogenomics of analgesic agents. Clin Ped Emerg Med 2007;8:262–7.
26. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyl transferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608–14.
27. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lötsch J, Roots I, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7:257–65.
28. Evans W, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487–91.
29. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, McDonagh EM, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112:1022–7.
30. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002; 1:259–66.
31. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993;341:436.
32. Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27:5972–8.
33. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336:225–9.

34. Schwab M, Schäffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12:429–36.
35. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;81:429–44.
36. Lötsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmöller J, Geisslinger G. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 2009; 144:119–24.
37. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577–9.
38. Stamer UM, Stüber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007;8:2235–45.
39. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–57.
40. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285–93.
41. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics 2009;10:1323–39.
42. Ni W, Ji J, Dai Z, Liu Y, Wang J, Zuo Y, et al. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS ONE 2010;5:e13792.
43. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985–9.
44. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 2008;359:789–99.
45. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391–400.

46. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992–5.
47. Trosko JE. The role of stem cells and gap junctions as targets for cancer chemoprevention and chemotherapy. Biomed Pharmacother 2005;59:326–31.
48. Guéant-Rodriguez RM, Guéant JL, Viola M, Rossi E, Campagna S, Romano A, et al. Association of tumor necrosis factor-alpha -308G>A polymorphism with IgE-mediated allergy to beta lactams in an Italian population. Pharmacogenomics J 2008;8:162–8.
49. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8:286–98.
50. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005;97:643–55.
51. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005;106:721–4.
52. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.
53. Karikas GA. Chemoprevention molecular and biochemical mechanisms involved in cancer control and management. Health Sci J 2011;5:149–56.
54. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009;8:1409–20.
55. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424–9.
56. Dang W, Steffen KK, Perry R, Dorsey JA, Johnson FB, Shilatifard A, et al. Histone H4 lysine16 acetylation regulates cellular lifespan. Nature 2009;459:802–7.
57. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with down regulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9:435–43.
58. Karikas GA. Natural and synthetic agents in cancer chemoprevention. Pharmakeftiki 2012;24:79–88.

59. Karikas GA. Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J BUON 2010;15:627–38.
60. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92.